Surgical Fibrin Formulation segmentation by application delineates four primary use‑cases: hemostasis, tissue adhesion, wound healing, and drug delivery. Hemostasis accounts for the largest share, roughly 40 % of total revenues, because fibrin sealants are routinely employed to achieve rapid clot formation in cardiovascular, hepatic and orthopedic procedures where intra‑operative bleeding poses a critical risk. Tissue adhesion, representing about 30 % of the market, leverages the adhesive properties of fibrin to replace sutures or staples in ophthalmic, otolaryngologic and reconstructive surgeries, driving demand for high‑strength, low‑toxicity formulations. Wound‑healing applications, contributing 20 %, focus on chronic ulcer management and post‑excisional repair, where the scaffold function of fibrin supports cellular migration and angiogenesis. The emerging drug‑delivery niche, at 10 %, integrates therapeutic agents within the fibrin matrix for localized release, expanding the market into oncology and regenerative medicine. Collectively, these application segments define the market taxonomy and shape investment priorities across product development and geographic expansion.